Search Results

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE).

Eli Lilly and Company and DICE Therapeutics, Inc. announced a definitive agreement for Lilly to acquire DICE.

Eli Lilly stands to gain access to DICE Therapeutics’ DELSCAPE platform, which enables the design of orally available molecules for autoimmune and inflammatory diseases.

DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company) today announced management will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023 at 3:00 p.m. PT / 6:00 p.m. ET.

Eli Lilly and Company announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares of common stock of DICE Therapeutics, Inc., for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding.

DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company) today announced management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 4:00 p.m. ET.

DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company) today reported financial results for the fourth quarter and full year ended December 31, 2022 and highlighted recent corporate achievements.

DICE Therapeutics, Inc. announced that management will host a research & development day on Tuesday, June 20, 2023 from 12:00 p.m. – 2:30 p.m. ET in New York, NY.

Drug development powered by artificial intelligence is countering incentives from the Inflation Reduction Act and making small molecules more attractive in the complex inflammatory & immunology disease space.

DICE Therapeutics, Inc. (Nasdaq: DICE) today announced that data from its Phase 1 proof-of-concept clinical trial of DC-806, an oral small molecule antagonist of the pro-inflammatory cytokine IL-17, will be presented in a late-breaking oral session at the 2023 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 17-21 in New Orleans, LA.